

LUNG CANCER AWARENESS MONTH

This Lung Cancer Awareness Month, BARC would like to take a moment to put the spotlight on the fight against Lung Cancer.

The World Cancer Research Fund (WCRF) estimated the number of Lung Cancer cases to 1.8 million in 2012. This number is expected to increase to 3.3 million by 2035.


Lung Cancer is the most prevalent cancer type worldwide, contributing to about 13% of the total number of reported cancer cases. Non-small cell lung cancer (NSCLC) accounts for the majority of Lung Cancer, correlating with about 85%.

GlobalData expects to see the value of the global drug market for NSCLC grow from \$6.21B in 2015 to \$26.8B in 2025. This corresponds with a forecasted CAGR of 15.7% (*GlobalData*).

For over 30 years, BARC provides Pharma and Biotech Companies with Central Laboratory Oncology Services in both routine and specialized testing such as Safety tests, Immunoassays, Histopathology, FISH, Flow Cytometry and Molecular Assays

Lung Cancer Incidence Forecast

Lung Cancer rates vary between men and women, with a global higher incidence rate for men. (*based on WCRF data*)



including Genetic profiling for various Oncology trials.

At BARC, experts in Oncology and other medical specialties operate as one, often under the same roof. Hence, BARC ensures that the offered tests are performed routinely for diagnostic purposes, inclusion/exclusion criteria, patient stratification, staging and follow-up.

BARC is a complete solution provider with the capability of offering diagnostic testing for various mutations and targets for a variety of FDA-approved Companion Diagnostics in NSCLC. Some examples are, but not limited to, (phospho)EGFR, EGFR T790M, ALK, ROS1, PD-1 and PD-L1 pathways.

Equipped with cutting-edge technologies, BARC's experts act as genuine partners and interact with our clients during the design of a study or proposing protocol refinements. Considering the complexity of many oncology trials, BARC often works closely with our clients to develop a tailor-made approach, customized to meet the specified requirements.

As a global central laboratory, BARC is proud to contribute to the development of new Lung Cancer treatments.

Sofie Vandevyver & Ishita Modi
 Scientific Liaisons Solid Oncology
 science@barclab.com
www.barclab.com

45% of oncology trials in the past 5 years

17% of our oncology trials are in Lung Cancer

BARC is helping to bring life-saving therapies to Lung Cancer Patients